<DOC>
	<DOCNO>NCT02031471</DOCNO>
	<brief_summary>This open-label , single-arm study evaluate efficacy , safety tolerability subcutaneously administer tocilizumab monotherapy and/or combination methotrexate non-biologic disease modify anti-rheumatic drug ( DMARDs ) participant active rheumatoid arthritis ( RA ) naïve tocilizumab . Participants receive tocilizumab 162 milligram ( mg ) subcutaneously weekly 24 week . Participants complete core study achieve least moderate European League Against Rheumatism ( EULAR ) response Week 24 may enter extension phase receive 28 week .</brief_summary>
	<brief_title>TOSCARA Study : A Study Subcutaneous Tocilizumab ( RoActemra/Actemra ) Participants With Active Rheumatoid Arthritis Naïve RoActemra/Actemra Treatment</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult participant , &gt; /= 18 year age Active moderate severe rheumatoid arthritis accord revise ( 1987 ) American College Rheumatology ( ACR ) criterion EULAR/ACR ( 2010 ) criterion Inadequate response intolerant previous therapy two nonbiologic diseasemodifying antirheumatic drug ( DMARDs ) , one methotrexate , administer optimal way least 3 month ; eligible participant may also inadequate responder maximum one biologic DMARD Oral corticosteroid ( &lt; /= 10 milligram per day ( mg/day ) prednisolone equivalent ) nonsteroidal antiinflammatory drug ( NSAIDs ; recommend dose ) permit stable dose regimen &gt; /= 4 week prior baseline Permitted DMARDs allow stable dose least 4 week prior baseline Receiving treatment outpatient basis , include tocilizumab Females childbearing potential male female partner childbearing potential must agree use reliable mean contraception define protocol Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow baseline long term extension ( LTE ) period Rheumatic autoimmune disease rheumatoid arthritis Functional Class IV define ACR Classification Functional Status Rheumatoid Arthritis Diagnosis juvenile idiopathic arthritis juvenile RA and/or RA age 16 Prior history current inflammatory joint disease RA Exposure tocilizumab ( intravenous subcutaneous ) time prior baseline Treatment investigational agent within 4 week ( 5 halflives investigational drug , whichever long ) screen Intraarticular parenteral corticosteroid within 4 week prior baseline History severe allergic anaphylactic reaction human , humanized murine monoclonal antibody Evidence serious concomitant disease disorder Known active current history recurrent infection Any major episode infection require hospitalization treatment IV antibiotic within 4 week screen oral antibiotic within 2 week screen Active Tuberculosis ( TB ) require treatment within previous 3 year Positive hepatitis B hepatitis C Primary secondary immunodeficiency ( history currently active ) Pregnant lactate woman Neuropathies condition might interfere pain evaluation Inadequate hematologic , renal liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>